{"schema_version":"secwatch.filing_event.v1","accession":"0001604821-26-000015","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2026-08-06T20:05:21+00:00","discovered_at":"2026-08-06T20:07:10.269219+00:00","generated_at":"2026-08-06T20:10:26.133751+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Natera Q2 revenue $752.8M (+37.7% YoY); raises FY2026 guidance by $100M","bullets":["Revenue $752.8M (+37.7% YoY); tests processed 1,043,900 (+22.4%); oncology tests 296,700 (+57.2%).","Net loss $67.0M ($0.47 diluted EPS) vs $100.9M ($0.74) in Q2 2025; operating loss $75.8M vs $110.4M.","Raised 2026 annual revenue guidance by $100M midpoint to $2.85B-$2.91B; gross margin ~64-66%.","Cash increased $3.6M in Q2 to $1,091.5M; debt $80.3M under UBS line at SOFR+50bps.","CEO cites Signatera regulatory approvals, Medicare coverage for Prospera, and Panorama NIPT launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001604821-26-000015","json":"https://secwatch.observer/filing/0001604821-26-000015.json","markdown":"https://secwatch.observer/filing/0001604821-26-000015.md","text":"https://secwatch.observer/filing/0001604821-26-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000160482126000015/0001604821-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000160482126000015/ntra-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:10:26.133751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}